Atherosclerosis Drugs Market Expected to Grow at 2.3% CAGR Through 2033

The current valuation of the global Atherosclerosis Drugs Market stands at US$ 49.9 billion, with a projected growth rate of 2.3% CAGR over the coming decade, reaching US$ 62.8 billion by 2033. The phenomenon of urbanization has triggered significant lifestyle shifts worldwide, leading to a surge in health complications such as high blood pressure, diabetes, cardiovascular diseases, and obesity. These prevalent health challenges are the primary drivers behind the demand for atherosclerosis drugs, with expectations of a gradual increase in demand over the next decade.

𝗚𝗲𝘁 𝗙𝗿𝗲𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝗽𝘆:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4434

Factors contributing to this anticipated rise include the aging population, a surge in cardiovascular disorders, escalating obesity rates, unhealthy dietary practices, sedentary lifestyles, and increased investments in healthcare research and development. These dynamics collectively hold promising potential for boosting the sales of atherosclerosis drugs in the foreseeable future.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗞𝗲𝘆 𝗗𝗿𝗶𝘃𝗲𝘀:

Rising Prevalence of Atherosclerosis:

With changing lifestyles and dietary habits, the prevalence of atherosclerosis is increasing globally. Sedentary lifestyles, high-fat diets, smoking, and other risk factors contribute to the development of this condition. As a result, there's a growing need for medications that can effectively manage and treat atherosclerosis.

Advancements in Drug Development:

Pharmaceutical companies are continuously investing in research and development to discover and develop new drugs for atherosclerosis. These advancements include novel drug delivery systems, targeted therapies, and combination treatments that offer improved efficacy and fewer side effects compared to traditional medications.

Growing Aging Population:

As the global population ages, the incidence of atherosclerosis-related diseases such as heart attacks and strokes is expected to rise. Older adults are more susceptible to developing atherosclerosis due to age-related changes in their arteries. This demographic trend is driving the demand for drugs that can prevent and treat atherosclerosis-related complications.

Increased Focus on Preventive Care:

Healthcare providers are increasingly emphasizing the importance of preventive care to reduce the burden of cardiovascular diseases. This includes lifestyle modifications such as regular exercise, healthy diet choices, and smoking cessation, as well as the use of medications to control cholesterol levels and blood pressure. As a result, there's a growing market for drugs that can help prevent the progression of atherosclerosis in high-risk individuals.

Emerging Therapeutic Approaches:

In addition to traditional cholesterol-lowering statin drugs, there's growing interest in novel therapeutic approaches for treating atherosclerosis. This includes drugs that target inflammation, immune responses, and other underlying mechanisms involved in the development and progression of the disease. These emerging therapies hold promise for improving outcomes for patients with atherosclerosis.

𝗙𝘂𝘁𝘂𝗿𝗲 𝗢𝘂𝘁𝗹𝗼𝗼𝗸:

Looking ahead, the atherosclerosis drugs industry is poised for continued growth and innovation. Advances in drug development, coupled with increasing awareness and emphasis on preventive care, are expected to drive market expansion. Pharmaceutical companies will continue to invest in research and development to bring new and improved therapies to market. Additionally, collaborations between academia, industry, and regulatory agencies will play a crucial role in advancing our understanding of atherosclerosis and developing effective treatments. Overall, the future looks promising for the atherosclerosis drugs industry as it strives to address the growing global burden of cardiovascular diseases.

𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗙𝗼𝗿 𝗙𝗥𝗘𝗘 𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗥𝗲𝗽𝗼𝗿𝘁:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=4434

𝗠𝗮𝗿𝗸𝗲𝘁 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀:

Merck & Co. Inc.
Sanofi
Hoffmann La-Roche Ltd.
Bayer AG
Pfizer Inc.
Novartis AG
GlaxoSmithKline Plc
Janssen Global Services LLC
Amgen Inc.
Mylan N.V.

𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲:

In August 2022, Cadila Pharmaceuticals, an Indian pharmaceutical company announced the launch of generic versions of sitagliptin, which is a drug class of DPP-4 inhibitors used for the treatment of hyperglycaemia that is known to lead to complications such as heart attacks, stroke, and atherosclerosis. The generic versions were launched under the brand names Sitenali and Jankey for type 2 diabetes in India.

Leading atherosclerosis drug manufacturers are focusing on obtaining approvals from regulatory authorities for their products to fast-track their launches.

Merck & Co. is focusing on obtaining approval for its drugs that are in the development pipeline to attain its revenue goal of US$ 10 billion in the mid-2030s. The company's atherosclerosis drug MK-0616 is in its phase 2B study that has an estimated completion timeline of February 2023. The drug is an oral treatment expected to lower cholesterol levels in an individual.

𝗕𝗿𝗼𝘄𝘀𝗲 𝗙𝘂𝗹𝗹 𝗥𝗲𝗽𝗼𝗿𝘁 @ https://www.factmr.com/report/4434/atherosclerosis-drugs-market

𝗠𝗮𝗿𝗸𝗲𝘁 𝗞𝗲𝘆 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻:

By Drug Class :
Anti-platelet Medications
Cholesterol-lowering Medications
Fibric Acid and Omega-3 Fatty Acid Derivatives
Beta Blockers
Angiotensin-converting Enzyme (ACE) Inhibitors
Calcium Channel Blockers
Diuretics
Others

By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region :
North America
Latin America
Europe
APAC
MEA

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:
US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.